Takeda Pharmaceutical Company Limited (NYSE: TAK) announced fiscal year 2025 results showing revenue decreased 1.7% to ¥4,505.7 billion, primarily due to loss of exclusivity for VYVANSE, which was partially offset by growth and launch products.

The Japanese pharmaceutical company reported operating profit increased 19.3% to ¥408.8 billion, while core operating profit rose 0.8% to ¥1,172.5 billion. Net profit jumped 77.7% to ¥191.8 billion, and earnings per share increased to ¥122 from ¥68 in the previous year.

Takeda achieved key pipeline milestones with positive Phase 3 results for oveporexton, rusfertide, and zasocitinib. The company completed regulatory submissions for oveporexton and rusfertide, with both receiving Priority Review designation from the U.S. FDA. Commercial launches are planned for the second half of 2026.

For fiscal year 2026, Takeda forecasts revenue of ¥4,640.0 billion and core operating profit of ¥1,160.0 billion. The company expects core revenue to decline in the low single digits and core operating profit to decrease 5% to 8% at constant exchange rates.

CEO-elect Julie Kim stated the company is positioned for growth through near-term product launches and has "the most robust late-stage pipeline in our history." CFO Milano Furuta noted the company delivered solid profit and cash flow through cost control while investing in new product launches.

Adjusted free cash flow totaled ¥684.5 billion, down from ¥769.0 billion in the previous year. The company proposed an annual dividend of ¥200 per share and ended the fiscal year with an adjusted net debt-to-EBITDA ratio of 2.6x.